Alexza's Last Stand: Hoping For Buyout Or License Of Adasuve
This article was originally published in The Pink Sheet Daily
Executive Summary
Facing a potential shutdown at the end of April, the California drug-delivery firm hopes either to be purchased by its Spanish partner or find a new licensee of US rights to its inhalable antipsychotic.
You may also be interested in...
Alexza Finds New U.S. Marketing Partner For Adasuve In Teva
A quick-acting, inhaled antipsychotic, Adasuve has been approved in the U.S. and EU, where it will be commercialized by Spain’s Grupo Ferrer. Teva takes over after previous U.S. partner Biovail stepped away upon being bought out by Valeant.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.